eli lilly clinical trials retatrutide Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Eli Lilly's trial of obesity

Articles written in the English language and published in peer-reviewed journals were included in the present review

Factors to consider: Budget : Both treatments are affordable, but Cavitation may require more sessions

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2025

Practical guardrails If your clients are weighing GLP-1 coverage, here are some of the strategies worth discussing: Conversations to have with clients right now Heres how to frame the discussion with HR and finance leaders: What to watch in 2026 Bottom Line GLP-1s are no longer a side note in benefits discussions

Mucosal Healing: Promotes regeneration of the intestinal lining, repairing ulcers, lesions, and other gut injuries